EAM
Eventide Asset Management Portfolio holdings
AUM
$5.71B
This Quarter Return
+8.64%
1 Year Return
+51.18%
3 Year Return
+209.28%
5 Year Return
+283.63%
10 Year Return
+1,480.39%
AUM
$7.44B
AUM Growth
+$7.44B
(+10%)
Cap. Flow
+$500M
Cap. Flow
% of AUM
6.72%
Top 10 Holdings %
Top 10 Hldgs %
25.63%
Holding
170
New
15
Increased
63
Reduced
24
Closed
16
Top Buys
| 1 |
Zymeworks
ZYME
|
$62.5M |
| 2 |
nCino
NCNO
|
$39.7M |
| 3 |
Shoals Technologies Group
SHLS
|
$37.4M |
| 4 |
Generac Holdings
GNRC
|
$36M |
| 5 |
argenx
ARGX
|
$35.8M |
Top Sells
| 1 |
Sarepta Therapeutics
SRPT
|
$52M |
| 2 |
Verisk Analytics
VRSK
|
$37M |
| 3 |
KRTX
Karuna Therapeutics, Inc. Common Stock
KRTX
|
$25.4M |
| 4 |
Okta
OKTA
|
$23.8M |
| 5 |
Neurocrine Biosciences
NBIX
|
$23.3M |
Sector Composition
| 1 | Healthcare | 35.75% |
| 2 | Technology | 29.25% |
| 3 | Industrials | 12.31% |
| 4 | Consumer Discretionary | 7.52% |
| 5 | Communication Services | 5.3% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
101
Xencor
XNCR
$594M
| $17.5M | 0.23% |
506,000
| – | – |
|
102
Ciena
CIEN
$13.4B
| $17.4M | 0.23% |
305,175
+17,000
| +6% | +$967K |
|
103
Prologis
PLD
$103B
| $16.5M | 0.22% |
138,200
+15,156
| +12% | +$1.81M |
|
104
KalVista Pharmaceuticals
KALV
$713M
| $16M | 0.21% |
665,681
-707,319
| -52% | -$16.9M |
|
105
Oric Pharmaceuticals
ORIC
$1.03B
| $15.5M | 0.21% |
876,948
+446,948
| +104% | +$7.91M |
|
106
Kura Oncology
KURA
$732M
| $14.7M | 0.2% |
704,000
-913,573
| -56% | -$19M |
|
107
Pentair
PNR
$17.5B
| $14.3M | 0.19% |
211,200
+32,500
| +18% | +$2.19M |
|
108
Equinix
EQIX
$74.6B
| $14.2M | 0.19% |
+17,693
| New | +$14.2M |
|
109
KLA
KLAC
$111B
| $13.4M | 0.18% |
41,398
+5,600
| +16% | +$1.82M |
|
110
First Horizon
FHN
$11.4B
| $13.3M | 0.18% |
771,000
-97,800
| -11% | -$1.69M |
|
111
908 Devices
MASS
$214M
| $12.9M | 0.17% |
333,283
| – | – |
|
112
Syndax Pharmaceuticals
SNDX
$1.39B
| $12.1M | 0.16% |
702,348
-1,314,645
| -65% | -$22.6M |
|
113
ARS Pharmaceuticals
SPRY
$1.08B
| $11.5M | 0.15% |
371,384
| – | – |
|
114
Synopsys
SNPS
$110B
| $11.2M | 0.15% |
40,757
+12,800
| +46% | +$3.53M |
|
115
SBA Communications
SBAC
$21.4B
| $11M | 0.15% |
34,600
+11,834
| +52% | +$3.77M |
|
116
IDEX
IEX
$12.1B
| $10.1M | 0.14% |
45,700
+8,000
| +21% | +$1.76M |
|
117
Pharvaris
PHVS
$1.41B
| $9.84M | 0.13% |
541,563
+41,563
| +8% | +$755K |
|
118
Synovus
SNV
$7.14B
| $9.66M | 0.13% |
220,200
-45,700
| -17% | -$2.01M |
|
119
Equity Lifestyle Properties
ELS
$11.7B
| $9.45M | 0.13% |
127,200
+31,900
| +33% | +$2.37M |
|
|
AESC
120
DELISTED
The AES Corporation
AESC
| $8.95M | 0.12% |
+83,200
| New | +$8.95M |
|
121
Bolt Biotherapeutics
BOLT
$9.29M
| $8.26M | 0.11% |
26,700
+10,553
| +65% | +$3.26M |
|
122
Design Therapeutics
DSGN
$339M
| $7.96M | 0.11% |
400,000
| – | – |
|
123
VF Corp
VFC
$5.79B
| $7.79M | 0.1% |
95,000
+13,400
| +16% | +$1.1M |
|
|
APTO
124
DELISTED
Aptose Biosciences, Inc.
APTO
| $7.63M | 0.1% |
5,109
| – | – |
|
125
American Water Works
AWK
$27.5B
| $7.54M | 0.1% |
48,900
+5,800
| +13% | +$894K |
|